[1]吴亚红,高艳锋,祁元明△.肿瘤抗原细胞毒性 T 淋巴细胞表位鉴定和多肽疫苗的研究进展*[J].郑州大学学报(医学版),2011,(05):657.
点击复制

肿瘤抗原细胞毒性 T 淋巴细胞表位鉴定和多肽疫苗的研究进展*
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2011年05期
页码:
657
栏目:
特约述评
出版日期:
2011-09-20

文章信息/Info

作者:
吴亚红高艳锋祁元明
郑州大学生物工程系 郑州 450001
关键词:
肿瘤抗原细胞毒性 T 淋巴细胞表位多肽疫苗

参考文献/References:

[1]Naz RK, Dabir P. Peptide vaccines against cancer, infectious diseases, and conception[J]. Front Biosci,2007,12:1833
[2]Kawakami Y. Cancer treatment by comprehensive regulation of antitumor immune network[J]. Nihon Rinsho, 2010, 68(6):1094
[3]Khazaie K, Bonertz A, Beckhove P. Current developments with peptidebased human tumor vaccines[J]. Curr Opin Oncol, 2009, 21(6):524
[4]Beck A, KlinguerHamour C, Bussat MC, et al. Peptides as tools and drugs for immunotherapies[J]. J Pept Sci, 2007, 13(9):588
[5]Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy[J]. Cancer Sci, 2009, 100(11):2014
[6]Almeida LG, Sakabe NJ, deOliveira AR, et al. CTdatabase: a knowledgebase of highthroughput and curated data on cancertestis antigens[J]. Nucleic Acids Res, 2009, 37(Database issue):D816
[7]Bao L, Dunham K, Lucas K. MAGEA1, MAGEA3, and NYESO1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocytemediated tumor cell killing[J]. Cancer Immunol Immunother,2011 May 28[Epub ahead of print]
[8]Reuschenbach M, Waterboer T, Wallin KL, et al. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPVassociated cancers[J]. Int J Cancer, 2008, 123(11):2626
[9]Gardiner J, Overall R, Marc J. Putative Arabidopsis homologues of metazoan coiledcoil cytoskeletal proteins[J]. Cell Biol Int, 2011,35(8):767
[10]Sahoo R, Babu VC, Harini VV, et al. Her2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options[J]. Onkologie, 2011, 34(7):356
[11]Tan HT, Low J, Lim SG, et al. Serum autoantibodies as biomarkers for early cancer detection[J]. FEBS J, 2009, 276(23):6880
[12]Lundegaard C, Lund O, Buus S, et al. Major histocompatibility complex class I binding predictions as a tool in epitope discovery[J]. Immunology, 2010, 130(3):309
[13]Doytchinova IA, Guan P, Flower DR. EpiJen: a server for multistep T cell epitope prediction[J]. BMC Bioinformatics, 2006, 7:131
[14]Lekka E, Gritzapis AD, Perez SA, et al. Identification and characterization of a HER2/neu epitope as a potential target for cancer immunotherapy[J]. Cancer Immunol Immunother, 2010, 59(5):715
[15]Li F, Yang D, Wang Y, et al. Identification and modification of an HLAA*0201restricted cytotoxic T lymphocyte epitope from Ran antigen[J]. Cancer Immunol Immunother, 2009, 58(12):2039
[16]Croft NP, Purcell AW. Peptidomimetics: modifying peptides in the pursuit of better vaccines[J]. Expert Rev Vaccines, 2011, 10(2):211
[17]Inoue M, Senju S, Hirata S, et al. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers[J]. Int J Cancer, 2010, 127(6):1393
[18]Gritzapis AD, Fridman A, Perez SA, et al. HER2/neu (657665) represents an immunogenic epitope of HER2/neu oncoprotein with potent antitumor properties[J]. Vaccine, 2009, 28(1):162
[19]Liu W, Zhai M, Wu Z, et al. Identification of a novel HLAA2restricted cytotoxic T lymphocyte epitope from cancertestis antigen PLAC1 in breast cancer[J]. Amino Acids, 2011 Jun 28[Epub ahead of print]
[20]Gritzapis AD, Voutsas IF, Lekka E, et al. Identification of a novel immunogenic HLAA*0201binding epitope of HER2/neu with potent antitumor properties[J]. J Immunol, 2008, 181(1):146
[21]Gao YF, Sun ZQ, Qi F, et al. Identification of a new broadspectrum CD8+ T cell epitope from overexpressed antigen COX2 in esophageal carcinoma[J]. Cancer Lett, 2009, 284(1):55
[22]Lv H, Gao Y, Wu Y, et al. Identification of a novel cytotoxic T lymphocyte epitope from CFP21, a secreted protein of Mycobacterium tuberculosis[J]. Immunol Lett, 2010, 133(2):94
[23]Amadori D, Milandri C, Comella G, et al. A phase Ⅰ/Ⅱ trial of nonpegylated liposomal doxorubicin, docetaxel and trastuzumab as firstline treatment in HER2positive locally advanced or metastatic breast cancer[J]. Eur J Cancer, 2011 Jun 10[Epub ahead of print]
[24]Claesson MH. Why current peptidebased cancer vaccines fail: lessons from the three Es[J]. Immunotherapy, 2009, 1(4):513
[25]Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines[J]. Nat Rev Cancer, 2008, 8(5):351.A
[26]Wang H, Su X, Zhang P, et al. Recombinant heat shock protein 65 carrying PADRE and HBV epitopes activates dendritic cells and elicits HBVspecific CTL responses[J]. Vaccine, 2011, 29(12):2328

相似文献/References:

[1]张毅),Michael Nishimura).肿瘤的细胞免疫治疗[J].郑州大学学报(医学版),2011,(02):165.

备注/Memo

备注/Memo:
*国家自然科学基金资助项目30872381,30901362   
△祁元明,女,教授,博士研究生导师,郑州大学生物工程系主任。主要从事肿瘤免疫、结核免疫与多肽药物的相关研究,为教育部高等学校生物科学与工程教学指导委员会委员,国家“863”项目与国家级精品课程评审专家,享受政府特殊津贴专家,中国生物化学与分子生物学会理事,河南省生物化学与分子生物学会副理事长,河南省杰出人才基金获得者,河南省教育厅学术与技术带头人。先后承担包括国家自然科学基金、河南省科技创新杰出人才基金、河南省重点科技攻关基金、河南省基础与前沿技术和河南省医学创新人才基金等项目。共发表论文80余篇,其中SCI论文14篇,研究成果获省部级科技进步二等奖3项、三等奖2项,国家发明专利2项。主编普通高等教育“十二·五”规划教材1部,副主编教材2部。
更新日期/Last Update: 2011-09-20